Discovery of CHK-336

PH1-3 (primary hyperoxalurias 1-3) are genetic diseases defined by elevated hepatic oxalate production and increased incidence of calcium oxalate kidney stones and potentially kidney failure. While treatments exist for PH1, none are approved for PH2 or PH3. LDHA (lactate dehydrogenase A) catalyzes the final step in hepatic oxalate synthesis and represents a potential therapeutic target for PH and other forms of hyperoxaluria driven by increased oxalate production. In this Flash Talk, Renata discusses the discovery of CHK-336, a novel oral small molecule that demonstrates potent and selective inhibition against the human LDH enzyme. CHK-336 demonstrated a liver-targeted tissue distribution profile in multiple species that is dependent on hepatic uptake by OATP transporters and target-mediated drug disposition. This presentation highlights the preclinical pharmacology of CHK-336, as well as early clinical study results in healthy volunteers (NCT05367661). By potently blocking LDH in the liver, where the majority of oxalate is produced, CHK-336 has the potential to treat all types of primary hyperoxaluria and other disorders resulting in increased oxalate production. 00:00 Welcome and Introduction 11:21 New DH Features 14:26 Presentation 48:22 Q&A If your company doesn’t have a subscription yet, reach out here to inquire about access: https://drughunter.com/plans Recorded on June 12th 2025, as a Drug Hunter Flash Talk. Sign up to be notified of future sessions here: https://drughunter.com/flash-talk-ser... Sign up for our free newsletter here: https://drughunter.com/newsletter-sig...